Category:

NiCE’s $955M Cognigy Deal Sets the Stage for Next-Gen AI Customer Experience

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– NiCE acquires Cognigy for $955M, aiming to unify conversational and agentic AI into its CXone Mpower platform.
– The deal strengthens enterprise AI offerings amid growing demand for automated, multilingual, and real-time customer service.
– Middle market tech and AI solution providers may see rising interest as companies seek scalable, AI-first platforms.

In a bold $955 million move that signals where the future of enterprise customer experience is headed, NiCE has announced the acquisition of Cognigy, a leader in conversational and agentic AI. With completion expected in Q4 2025, this acquisition could significantly reshape how enterprises approach customer service automation in an increasingly AI-centric world.

While broader markets remain focused on tech behemoths, NiCE’s acquisition is a reminder that innovation often comes from the middle tier—where agility meets ambition. The integration of Cognigy’s platform into NiCE’s CXone Mpower cloud system represents a significant leap in unifying front and back-office operations through AI. For companies in the small to mid-cap space, this is a signal worth watching.

Amid legal hurdles and compliance uncertainties surrounding generative AI, NiCE is steering into a niche that is rapidly evolving—agentic AI. These systems go beyond chatbots, offering autonomous agents capable of making real-time decisions, learning from interactions, and supporting human agents across more than 100 languages. This capability can dramatically improve the efficiency of customer-facing teams while preserving the nuance that customer relationships require.

For investors looking at enterprise tech from a middle-market lens, this deal aligns with key themes: the rising value of AI-powered operational tools, increased demand for multilingual and global customer engagement, and the long-term trend of digital-first infrastructure in traditional sectors.

The opportunity here isn’t just about NiCE’s expansion—it’s about what it signals for the broader CX and AI ecosystem. As mid-sized companies continue to digitize customer service operations, acquisitions like this underscore how mission-critical platforms are becoming central to business continuity and differentiation.

With heavyweights like Gartner and Forrester already recognizing NiCE as a category leader, this deal could further solidify its position. Meanwhile, Cognigy’s established client base—including brands like Lufthansa, DHL, and Toyota—adds global credibility and momentum.

For small and micro-cap investors, this may present a ripple effect: increased demand for specialized AI services, rising valuations for scalable automation platforms, and new acquisition interest in the CX tech sector. As AI continues its march into every corner of business, the middle market is proving to be not just reactive, but a proactive player in shaping its future.

Paramount-Skydance Merger Clears FCC: What It Means for Media Investors in a Shifting Landscape

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– The FCC has approved the $8.4 billion merger between Paramount Global and Skydance Media, removing the final regulatory obstacle.
– Skydance commits to overhauling CBS News with more balanced reporting and local news partnerships—shifting the tone of legacy media.
– The move signals potential for small- and mid-cap media disruption as legacy players face structural and ideological realignments.

The media and entertainment sector just experienced a seismic shift. On Thursday, the Federal Communications Commission formally approved the merger between Paramount Global and Skydance Media, clearing the path for the $8.4 billion transaction to move forward after more than a year of political, legal, and corporate wrangling.

For middle-market investors, this isn’t just a high-profile media headline—it’s a signal that the evolving definition of “legacy media” may be up for grabs. And where industry giants restructure, there’s often room for nimble upstarts and niche players to gain ground.

A Changing Media DNA

FCC Chair Brendan Carr cited a broad loss of public trust in national media outlets as one reason behind his approval, applauding Skydance’s commitment to overhaul CBS News. Among the pledges: appointing a CBS News ombudsman to oversee complaints of editorial bias, eliminating DEI initiatives, and reinforcing politically diverse viewpoints across CBS’s programming.

Whether investors agree with the ideological implications or not, the bottom line is clear: content strategies are becoming politically relevant assets, and media companies are increasingly shaped by the regulatory and cultural tides they navigate.

The New Power Map

The merger makes David Ellison’s Skydance the controlling force behind a sprawling content empire—Paramount Pictures, CBS, Paramount+, Nickelodeon, MTV, BET, Comedy Central, and more. With streaming growth plateauing and cord-cutting accelerating, the question becomes: How does new leadership monetize legacy assets in a digital-first world?

This moment may also introduce new competition among smaller digital studios, regional broadcasters, and emerging news platforms that offer alternative models. For investors eyeing undervalued or lesser-known content providers, this reshuffle could unlock new opportunity in the mid- and micro-cap space—especially those targeting niche audiences or regional news coverage.

Political Undercurrents Not Lost on Markets

Notably, the merger approval comes on the heels of a controversial $16 million legal settlement between Paramount and President Trump over a past CBS interview edit. Trump has publicly suggested that further ad or PSA commitments could follow from the new ownership, though Paramount denies any knowledge beyond the settlement itself.

While Commissioner Anna Gomez, the FCC’s lone Democrat, dissented on grounds of press freedom concerns, her vote was ultimately overruled. The outcome reveals the current FCC’s willingness to intervene not just on business terms, but cultural and editorial direction—adding a layer of unpredictability to future M&A in this space.

For media investors, especially those focused on growth opportunities in under-the-radar or mission-driven companies, the Paramount-Skydance merger opens the door to a new cycle of disruption. Whether the focus is hyperlocal news, politically agnostic reporting, or digitally native content strategies, now is the time to pay attention to overlooked players poised to benefit from this ideological and structural realignment in U.S. media.

Take a look at Noble Capital Markets’ Research Analyst Michael Kupinski’s coverage list for more emerging growth media companies.

Release – ACCO Brands Corporation Declares Quarterly Dividend

Posted on by aweinsoff@channelchek.com

Research News and Market Data on ACCO

07/25/2025

    LAKE ZURICH, Ill.–(BUSINESS WIRE)– ACCO Brands Corporation (NYSE: ACCO) today announced that its board of directors has declared a quarterly cash dividend of $0.075 per share. The dividend will be paid on September 10, 2025, to stockholders of record as of the close of business on August 22, 2025.

    About ACCO Brands Corporation
    ACCO Brands is the leader in branded consumer products that enable productivity, confidence and enjoyment while working, when learning and while playing. Our widely recognized brands include AT-A-GLANCE®, Five Star®, Kensington®, Leitz®, Mead®, PowerA®, Swingline®, Tilibra® and many others. More information about ACCO Brands Corporation (NYSE: ACCO) can be found at www.accobrands.com.

    Chris McGinnis
    Investor Relations
    (847) 796-4320

    Kori Reed
    Media Relations
    (224) 501-0406

    Source: ACCO Brands Corporation

    Trump Raises Trade Stakes: EU Talks Hang in Balance as Japan Deal Sparks Profit Dispute

    Posted on by slightbourne@noblecapitalmarkets.com

    President Trump on Friday put the likelihood of a trade agreement with the European Union at “50-50,” casting a shadow over negotiations that had shown signs of momentum in recent weeks. With an August 1 deadline looming, both sides had expressed optimism that a deal could be reached, but Trump’s remarks suggest growing skepticism — or a last-minute negotiating tactic. The European Commission’s president is set to meet Trump this weekend at his golf course in Scotland in what may be a final push to secure an agreement.

    Simultaneously, complications are surfacing in a newly announced trade deal with Japan. Just days after Trump unveiled the $550 billion Japanese investment and a baseline 15% tariff on Japanese imports, reports indicate that Tokyo and Washington are already at odds over how profits will be shared. Japan is seeking a structure tied to its sizable capital contribution, while U.S. negotiators insist on retaining as much as 90% of profits, citing regulatory, tax, and infrastructure advantages offered to foreign investors. The discord raises questions about whether this marquee deal can remain intact — or if it’s the first crack in what could become a patchwork of volatile trade relationships.

    Trump’s comments come as the administration prepares to issue formal letters to over 200 nations, outlining revised tariff schedules that will reportedly range from 15% to 50% depending on the nature of each bilateral relationship. The President indicated that more punitive tariffs are likely for nations that have either resisted new trade talks or failed to reach favorable terms, singling out Canada as a continued source of frustration. He suggested a 35% tariff could be imposed on Canadian imports not protected under the USMCA agreement, reigniting tensions with one of America’s largest trading partners.

    Elsewhere, new details emerged about recent U.S. deals with the Philippines and Indonesia. Both countries will see their exports to the U.S. hit with a 19% tariff, adding to the growing list of nations now operating under a Trump-era trade framework defined by high tariffs and deal-by-deal arrangements. Meanwhile, China remains in the mix, with Trump noting that the two sides now have the “confines of a deal” in place ahead of upcoming talks. Whether those talks produce meaningful outcomes or simply delay further escalation remains to be seen.

    Taken together, this flurry of trade activity signals a significant reshaping of global commerce under Trump’s second term. With tariffs now functioning not only as economic tools but also as political levers, the landscape for investors is shifting rapidly. Industries tied to global supply chains — particularly those reliant on imports — could face tighter margins, delayed deliveries, and strategic realignment. On the flip side, the push for domestic manufacturing and reshoring may boost middle-market industrials, infrastructure firms, and logistics providers.

    While the tone of Trump’s trade doctrine remains combative, the opportunities for agile investors are growing clearer. As countries jockey for favorable terms and multinationals rethink their sourcing strategies, small and mid-cap companies operating domestically could be among the biggest beneficiaries. Whether these deals hold or fall apart, one thing is certain: the age of blanket trade agreements is giving way to a more fragmented, transactional world economy — and that’s a game middle-market investors should be watching closely.

    Release – CVG Announces Second Quarter 2025 Earnings Call

    Posted on by aweinsoff@channelchek.com

    Research News and Market Data on CVGI

    July 24, 2025

    NEW ALBANY, Ohio, July 24, 2025 (GLOBE NEWSWIRE) — Commercial Vehicle Group (the “Company” or “CVG”) (NASDAQ: CVGI) will hold its quarterly conference call on Tuesday, August 5, 2025, at 8:30 a.m. ET, to discuss second quarter 2025 financial results. CVG will issue a press release and presentation prior to the conference call.

    Toll-free participants dial (800) 549-8228 using conference code 72110. International participants dial (289) 819-1520 using conference code 72110. This call is being webcast and can be accessed through the “Investors” section of CVG’s website at ir.cvgrp.com where it will be archived for one year.

    A telephonic replay of the conference call will be available until August 19, 2025. To access the replay, toll-free callers can dial (+1) 888 660 6264 using access code 72110 #, and toll callers in North America and other locations can dial (+1) 289 819 1325.

    About CVG

    At CVG, we deliver real solutions to complex design, engineering and manufacturing problems while creating positive change for our customers, industries, and communities we serve. Information about the Company and its products is available on the internet at www.cvgrp.com.

    Investor Relations Contact:
    Ross Collins or Stephen Poe
    Alpha IR Group
    CVGI@alpha-ir.com

    Primary Logo

    Source: Commercial Vehicle Group, Inc.

    Release – NN, Inc. to Hold Second Quarter 2025 Earnings Conference Call on Thursday, August 7, 2025

    Posted on by aweinsoff@channelchek.com

    Research News and Market Data on NNBR

    PDF Version

    CHARLOTTE, N.C., July 24, 2025 (GLOBE NEWSWIRE) — NN, Inc. (NASDAQ: NNBR), a global diversified industrial company that engineers and manufactures high-precision components and assemblies, announced today that it will release its second quarter 2025 financial results for the period ended June 30th, 2025, after the close of the market on Wednesday, August 6th, 2025. The Company will hold a related conference call on Thursday, August 7th, 2025, at 9:00 a.m. E.T. Participants on the call are asked to register five to ten minutes prior to the scheduled start time by dialing 1-888-999-3182 and from outside the U.S. at 1-848-280-6330.

    The conference call will be webcast simultaneously and in its entirety through the NN, Inc. Investor Relations website. Shareholders, media representatives and others may participate in the webcast by registering through the Investor Relations section on the company’s website at https://investors.nninc.com/.

    For those who are unavailable to listen to the live call, a replay will be available shortly after the call on NN’s website through August 8th, 2026.

    About NN, Inc.
    NN, Inc., a global diversified industrial company, combines advanced engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision components and assemblies for a variety of markets on a global basis. Headquartered in Charlotte, North Carolina, NN has facilities in North America, Europe, South America, and Asia. For more information about the company and its products, please visit www.nninc.com.

    Investor Relations:
    Joe Caminiti or Stephen Poe
    NNBR@alpha-ir.com
    312-445-2870

    Primary Logo

    Source: NN, Inc.

    Release – The Oncology Institute Announces Second Quarter 2025 Earnings Release Date and Conference Call

    Posted on by aweinsoff@channelchek.com

    Research News and Market Data on TOI

    Jul 24, 2025

    PDF Version

    CERRITOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) — The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that the company will release its second quarter 2025 financial results after the market close on Wednesday, August 13, 2025, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time).

    The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13754165. The replay will be available until Wednesday, August 20, 2025.

    Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the Investor Relations section of the Company’s website at https://investors.theoncologyinstitute.com/.

    About The Oncology Institute

    Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of over 1.8 million patients including clinical trials, transfusions, and other services traditionally associated with the most advanced care delivery organizations. With over 120 employed clinicians and more than 700 teammates in over 70 clinic locations, TOI is changing oncology for the better. For more information, visit www.theoncologyinstitute.com

    Contacts

    Media

    The Oncology Institute, Inc.
    marketing@theoncologyinstitute.com

    Investors

    ICR Healthcare
    TOI@icrhealthcare.com

    Release – GeoVax to Advance Gedeptin(R) into First-Line Therapy Neoadjuvant Combination Trial Following Landmark KEYNOTE-689 Results

    Posted on by aweinsoff@channelchek.com

    Research News and Market Data on GOVX

      Revised Phase 2 Strategy Targets Event-Free Survival in Primary Head and Neck Cancer through Checkpoint Inhibitor Combination

      ATLANTA, GA, July 24, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced a strategic shift in its Gedeptin® clinical development program, with a new emphasis on evaluating Gedeptin as a neoadjuvant therapy in combination with pembrolizumab for patients with primary, resectable head and neck squamous cell carcinoma (HNSCC).

      The revised strategy follows the landmark results of the KEYNOTE-689 Phase 3 trial, published in the New England Journal of Medicine on June 18, 2025, which demonstrated a significant improvement in event-free survival (EFS) with the addition of perioperative pembrolizumab in resectable, locally advanced HNSCC patients. These data represent the first validated use of PD-1 inhibition in curative-intent HNSCC and have catalyzed a major shift in treatment paradigms toward neoadjuvant immunotherapy.

      GeoVax’s new Phase 2 trial (AdPNP-203) will evaluate the addition of intra-tumoral Gedeptin®, intravenous fludarabine, and pembrolizumab in patients eligible for curative surgery. The trial is designed to assess major pathological response (MPR) and associated immunologic and biomarker outcomes following two pre-surgical cycles of therapy as well as event-free survival over a one-year period. Gedeptin’s tumor-targeting, immune-sensitizing mechanism may help overcome the limitations of checkpoint monotherapy by enhancing immune activation within the tumor microenvironment. Trial initiation is planned for 2026.

      “The KEYNOTE-689 results support our view that neoadjuvant checkpoint inhibition can transform the treatment of head and neck cancer,” said Dr. Kelly McKee, Chief Medical Officer at GeoVax. “By integrating Gedeptin into this emerging standard, we hope to improve both local tumor clearance and event-free survival, especially for high-risk or PD-L1-low patients.”

      “This is a strategic shift in our program,” added David Dodd, Chairman and CEO of GeoVax. “We believe Gedeptin’s localized cytotoxic mechanism, when combined with systemic checkpoint inhibition for first-line treatment, can meaningfully improve therapeutic outcomes in patients with resectable HNSCC.”

      Rationale for Combination Strategy

      As highlighted in the NEJM editorial, the benefit in KEYNOTE-689 may be driven primarily by the neoadjuvant component of immunotherapy. However, many patients still experience local or distant relapse, underscoring the need for intensified strategies in the perioperative window. Gedeptin, with its dual cytotoxic and immune-priming mechanism, may serve as an ideal partner to checkpoint inhibitors by converting “cold” tumors into “hot” immunogenic targets.

      About Gedeptin®

      Gedeptin is a gene-directed enzyme prodrug therapy (GDEPT) using a non-replicating adenoviral vector encoding purine nucleoside phosphorylase (PNP). Once delivered directly into tumors and followed by fludarabine, PNP enzymatically converts the prodrug into a cytotoxic compound, selectively targeting tumor cells while sparing healthy tissue. This localized approach aims to reduce toxicity, enhance immune visibility, and enable immune checkpoint synergy.

      Gedeptin has received Orphan Drug Designation for oral and pharyngeal cancers and is backed by a robust intellectual property portfolio. GeoVax’s ongoing innovation in immune-sensitizing therapies supports a broader strategy to complement checkpoint inhibitors and overcome tumor immune resistance across solid tumor types.

      About GeoVax

      GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.

      Forward-Looking Statements

      This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.

      Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

      Company Contact:

      info@geovax.com

      678-384-7220

      Investor Relations Contact:

      geovax@precisionaq.com

      212-698-8696

      Media Contact:

      Jessica Starman

      media@geovax.com

      Release – Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology

      Posted on by aweinsoff@channelchek.com

      Research News and Market Data on UNCY

      July 24, 2025 8:00am EDT Download as PDF

      OLC was well-tolerated and enabled serum phosphate control in over 90% of patients with a low pill burden

      LOS ALTOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced the publication of pivotal trial data describing the safety and tolerability of oxylanthanum carbonate (OLC) in chronic kidney disease (CKD) patients on dialysis in the Clinical Journal of the American Society of Nephrology.

      The publication, entitled “A Phase 2 Clinical Trial of Oxylanthanum Carbonate in Patients Receiving Maintenance Hemodialysis with Hyperphosphatemia,” examines the safety and tolerability of OLC at clinically effective doses with a goal serum phosphate concentration of ≤5.5 mg/dL. Eighty-six patients were treated with OLC in this open-label single arm Phase 2 study. At screening, only 59% of patients had serum phosphate levels of ≤5.5 mg/dL (phosphate control). OLC was well tolerated and enabled serum phosphate control in >90% of patients with a low pill burden (two-thirds of patients receiving three or fewer tablets/day). Pharmacokinetic analysis showed that systemic absorption of OLC (measured as lanthanum) was minimal to none in CKD patients.

      “With the favorable tolerability, strong efficacy and low pill burden highlighted in this prestigious publication, we continue to believe that OLC has the potential to offer patients a new option that could help improve adherence to treatment over time,” said Shalabh Gupta, MD, Chief Executive Officer of Unicycive. “This pivotal study was the final clinical evidence needed for our NDA package. We continue to collaborate closely with the U.S. Food and Drug Administration as we address their outstanding manufacturing questions and align on a path forward to bring OLC to this underserved patient population as quickly as possible.”

      Key Findings:

      • More than 90% of patients with hyperphosphatemia taking OLC achieved effective phosphate control.
      • Two-thirds of patients required three or fewer OLC tablets per day to achieve target serum phosphate levels, with most requiring no more than one tablet with each meal.
      • OLC was well tolerated in CKD patients on dialysis. The most common treatment-related adverse events were gastrointestinal (9% diarrhea; 6% vomiting) and only 4% of patients discontinued treatment due to treatment-related adverse events.

      “Despite the various treatment options available, there remains a significant need in managing hyperphosphatemia, which heavily impacts people with chronic kidney disease on dialysis,” said Dr. Pablo Pergola, MD, PhD, Research Director, Clinical Advancement Center, Renal Associates, P.A., and principal investigator of the trial. “These data add to the growing body of clinical evidence supporting the potential of OLC as an innovative treatment option, demonstrating effective phosphate control and reducing pill burden. OLC’s unique profile offers a promising alternative with favorable tolerability, potentially transforming the standard of care for patients.”

      The full publication can be accessed here and on the Presentations & Research page of Unicycive’s website.

      About Oxylanthanum Carbonate (OLC)
      OLC is an investigational oral phosphate binder that leverages proprietary nanoparticle technology to deliver high phosphate binding potency, reducing the number and size of pills that patients must take to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. Its potential best-in-class profile may have meaningful patient adherence benefits over currently available treatment options as it requires a lower pill burden.

      Unicycive is seeking FDA approval of OLC via the 505(b)(2) regulatory pathway. The NDA submission package is based on data from three clinical studies (a Phase 1 study in healthy volunteers, a bioequivalence study in healthy volunteers, and a tolerability study of OLC in CKD patients on dialysis), multiple preclinical studies, and the chemistry, manufacturing and controls (CMC) data. OLC is protected by a strong global patent portfolio including issued patents on composition of matter with exclusivity until 2031, and with the potential for patent term extension until 2035.

      About Hyperphosphatemia
      Hyperphosphatemia is a serious medical condition that occurs in nearly all patients with End Stage Renal Disease (ESRD). Annually there are over 450,000 individuals in the U.S. that require medication to control their phosphate levels.1 Uncontrolled hyperphosphatemia is strongly associated with increased death and hospitalization for CKD patients on dialysis. Treatment of hyperphosphatemia is aimed at lowering serum phosphate levels via two means: (1) restricting dietary phosphorus intake; and (2) using, on a daily basis, and with each meal, oral phosphate binding drugs that facilitate fecal elimination of dietary phosphate rather than its absorption from the gastrointestinal tract into the bloodstream.

      1Flythe JE. Dialysis-Past, Present, and Future: A Kidney360 Perspectives Series. Kidney360. 2023 May 1;4(5):567-568. doi: 10.34067/KID.0000000000000145. Epub 2023 Jun 29. PMID: 37229723; PMCID: PMC10371371.

      About Unicycive Therapeutics
      Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted Orphan Drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.

      Forward-looking statements
      Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Unicycive’s expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive’s current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, which could seriously harm our financial condition and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

      Investor Contacts:

      Kevin Gardner
      LifeSci Advisors
      kgardner@lifesciadvisors.com

      Media Contact:

      Rachel Visi
      Real Chemistry
      redery@realchemistry.com

      SOURCE: Unicycive Therapeutics, Inc.

      Primary Logo

      Source: Unicycive Therapeutics, Inc.

      Released July 24, 2025

      Release – Kelly Announces Second-Quarter 2025 Conference Call

      Posted on by aweinsoff@channelchek.com

      Research News and Market Data on KELYA

      July 24, 2025

      PDF Version

      TROY, Mich., July 24, 2025 (GLOBE NEWSWIRE) — Kelly, a leading global specialty talent solutions provider, will release its second-quarter earnings before the market opens on Thursday, August 7, 2025. In conjunction with its earnings release, Kelly will publish a financial presentation and host a live webcast of a conference call with financial analysts at 9 a.m. ET on August 7 to review the results from the quarter and answer questions.

      The presentation and a link to the live webcast will be accessible through the Company’s public website on the Investor Relations page under Events & Presentations. The webcast will be recorded, and a replay will be available within one hour of completion of the event through the same link as the live webcast.

      About Kelly

      Kelly Services, Inc. (Nasdaq: KELYA, KELYB) helps companies recruit and manage skilled workers and helps job seekers find great work. Since inventing the staffing industry in 1946, we have become experts in the many industries and local and global markets we serve. With a network of suppliers and partners around the world, we connect more than 400,000 people with work every year. Our suite of outsourcing and consulting services ensures companies have the people they need, when and where they are needed most. Headquartered in Troy, Michigan, we empower businesses and individuals to access limitless opportunities in industries such as science, engineering, technology, education, manufacturing, retail, finance, and energy. Revenue in 2024 was $4.3 billion. Learn more at kellyservices.com.

      KLYA-FIN

      Analyst & Media Contact:
      Scott Thomas
      (248) 251-7264
      scott.thomas@kellyservices.com

      AEye Soars After Apollo Lidar Becomes Core to NVIDIA’s Self-Driving Platform

      Posted on by slightbourne@noblecapitalmarkets.com
      Key Points:
      – AEye’s Apollo lidar is now fully integrated into NVIDIA’s DRIVE AGX platform.
      – The partnership gives AEye access to top global automakers and positions it as a key supplier in autonomous driving.
      – Apollo’s software-defined architecture and long-range sensing provide a scalable edge for smart mobility applications.

      Shares of AEye, Inc. (Nasdaq: LIDR) surged Thursday after the company announced a major milestone: its flagship Apollo lidar sensor is now fully integrated into NVIDIA’s DRIVE AGX platform, a central hub in the autonomous driving world. This integration isn’t just a technical step — it’s a commercial launchpad that could put AEye’s technology inside millions of vehicles over the next decade.

      NVIDIA’s DRIVE ecosystem is used by top-tier automakers globally, from early autonomous pioneers to traditional OEMs embracing next-gen driver assistance. By becoming an official component of the DRIVE AGX suite, AEye now has direct access to these automakers — positioning it as a go-to lidar provider in the race toward self-driving adoption.

      AEye’s Apollo sensor, part of the company’s 4Sight™ Flex lidar family, offers a unique mix of long-range detection (up to 1 km), compact design, and software-defined capabilities. That last point may be the most compelling: Apollo’s software-defined nature means the sensor can receive over-the-air updates, just like a smartphone, enabling continuous improvement without physical replacement.

      “This is how vehicles are being built today — smarter, more connected, and designed to evolve,” said CEO Matt Fisch. “Being certified on NVIDIA DRIVE AGX validates our approach and puts us on a direct path to global scale.”

      AEye’s technology isn’t just another lidar unit. Apollo is designed to integrate seamlessly into modern vehicle architecture, including behind the windshield — a feat many competitors struggle with due to limitations in wavelength and range. By using 1550 nm wavelength lidar, Apollo combines safety-critical resolution with the ability to remain aesthetically unobtrusive, a growing demand among automakers.

      Beyond the automotive world, AEye teased broader ambitions. The company plans to unveil OPTIS, a full-stack physical AI solution aimed at transportation, infrastructure, and security markets. This suggests that AEye is thinking bigger — positioning itself as not just a lidar company, but as a smart sensing platform ready to power everything from autonomous delivery vehicles to smart cities.

      For small- and micro-cap investors, AEye’s NVIDIA milestone offers a compelling glimpse of what success looks like in the sensor space: strategic partnerships, scalable architecture, and technology that fits into how mobility is evolving. With software-defined sensing quickly becoming the industry standard, Apollo’s adoption through NVIDIA could be the early signal of significant commercial momentum.

      AEye’s upcoming July 31 earnings call is expected to provide more clarity on the NVIDIA partnership’s revenue potential, as well as early market response to OPTIS.

      In a market where many lidar startups have stumbled, AEye’s continued focus on performance, integration, and flexibility is starting to separate it from the pack — and now, with NVIDIA in its corner, its road ahead may be wide open.

      Travelzoo (TZOO) – Steps On The Customer Acquisition Accelerator

      Posted on by slightbourne@noblecapitalmarkets.com


      Thursday, July 24, 2025

      Travelzoo® provides its 30 million members with exclusive offers and one-of-a-kind experiences personally reviewed by our deal experts around the globe. We have our finger on the pulse of outstanding travel, entertainment, and lifestyle experiences. We work in partnership with more than 5,000 top travel suppliers—our long-standing relationships give Travelzoo members access to irresistible deals.

      Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

      Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

      Refer to the full report for the price target, fundamental analysis, and rating.

      Mixed second quarter results. Revenues significantly increased 13.1% to $23.9 million, a sequential quarterly increase from 5.3% in Q1, reflecting its strategic shift toward a subscription based model. Adj. EBITDA fell short of our expectations, however, due to a step up in customer acquisition spend and the purchase of “distressed” vouchers. 

      Favorable customer acquisition dynamics. Customer acquisition costs went up in Q2 to $38 from $28 in Q1, but still remains positive. Total return is $58, $40 from the annual subscription fee and $18 from transactions. Management anticipates to continue to aggressively spend on customer acquisition in light of the favorable Return on Investment. These moves support a longer term attractive revenue outlook, but have a near term adverse impact on adj. EBITDA.


      Get the Full Report

      Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

      This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

      *Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

      FreightCar America (RAIL) – Updating Our Forward Estimates and Increasing our PT

      Posted on by slightbourne@noblecapitalmarkets.com


      Thursday, July 24, 2025

      Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

      Refer to the full report for the price target, fundamental analysis, and rating.

      Increasing longer-term rail car delivery estimates. While we have maintained our rail car delivery estimates for 2025 through 2027, we have increased our delivery estimates for 2028 through 2030. We now forecast rail car deliveries of 5,500, 5,750, and 6,000, respectively, compared with our prior estimates of 5,000, 5,000, and 5,000. While we had previously assumed that RAIL would operate four production lines with an aggregate capacity of 5,000 rail cars through 2030, we now assume the company will operate five production lines with a total capacity of 6,250 rail cars beginning in 2028. Our prior assumption had been that the company could begin producing a new line of higher-margin tank cars using existing capacity at the expense of lower margin products. Because we think tank cars could add an incremental 500 or more orders beginning in 2028, the tank cars would be incremental to existing orders with five production lines.

      Updating earnings estimates. We forecast 2025 EBITDA and EPS of $45.9 million and $0.47, respectively, while our 2026 estimates are $48.6 million and $0.53. While our 2025 and 2026 EBITDA estimates are unchanged, we have increased our forward estimates, which may be found in the financial model at the end of this report. While our earnings estimates have increased, gross margin as a percentage of sales remains unchanged at 13.0%, 13.3%, 13.5%, and 13.8% in 2027, 2028, 2029, and 2030, respectively, while selling, general, and administrative expense as a percentage of sales increased modestly. 


      Get the Full Report

      Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

      This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

      *Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.